This indefinite delivery contract was awarded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH) under the Department of Health and Human Services (HHS). The contract, valued at up to $74,995,000, is a multiple award with Advanced Bioscience Laboratories, Inc. (ABL) as the prime contractor.
The contract supports the PREVENT Cancer Preclinical Drug Development Program, with the objective of cGMP production of vaccines and biologicals for cancer prevention. Key products and services include the manufacture of a vaccine targeting frame-shift mutations characteristic of tumors with microsatellite instability, as well as a range of other preclinical and clinical development support services such as process development, analytical testing, stability studies, and project management for infectious disease countermeasures and cancer-related therapeutics. The contract has a current period of performance from September 2019 to July 2020, with potential extension through May 2024. There is no set-aside designation indicated for this contract or the specific task order awarded to date, valued at $4,174,177.97.
Generated 9/7/24, 10:23 AM